Skyrizi vs Tremfya
both IL-23 inhibitors reviewed for plaque psoriasis
Skyrizi(risankizumab-rzaa)
AbbVie Inc. · 3590 cited findings →
Tremfya(guselkumab)
Johnson & Johnson · 4746 cited findings →
What the regulatory reviews say
Skyrizi and Tremfya are both IL-23 inhibitors reviewed for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Skyrizi was also reviewed for active psoriatic arthritis in adults and moderate to severe plaque psoriasis in children and adolescents from the age of 6 years. Tremfya was also reviewed for active psoriatic arthritis in adult patients and moderately to severely active ulcerative colitis in adult patients, and moderate to severe plaque psoriasis in children and adolescents from the age of 6 years.
In its review, Skyrizi demonstrated a sPGA 0 or 1 response rate of 61%. Tremfya's review noted an IGA 0/1 response rate of 100.0% and statistically significant results for clinical remission (primary endpoint).
These drugs were studied in separate trials with different designs, populations, and timepoints, and with different endpoints and comparators. The figures presented are from each drug's own review documents and are not head-to-head comparisons; neither drug is presented as superior.
Each drug's own results — cited
| Skyrizi | Tremfya | |
|---|---|---|
| Approval Date | April 23, 2019 ABBVIE INC — Skyrizi FDA Review (NDA/BLA 761105, 2024), p.1 | September 11, 2024 JANSSEN BIOTECH — Tremfya FDA Review, p.1 |
| Plaque Psoriasis Response Rate | 61 sPGA 0 or 1 response rate (%) ABBVIE INC — Skyrizi FDA Review (NDA/BLA 761105, 2024), p.21 | 100.0 IGA 0/1 response rate Johnson & Johnson — Tremfya FDA Review, p.243 |
Explore the full evidence
Every cited finding behind both drugs is in the Immunology research library →
Figures are as stated in the cited regulatory review documents. Educational reference only — not medical or investment advice.